Zacks Research Issues Negative Outlook for Alkermes Earnings

Alkermes plc (NASDAQ:ALKS) – Analysts at Zacks Research lowered their Q2 2025 EPS estimates for shares of Alkermes in a research note issued on Monday, January 6th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.31 for the quarter, down from their previous estimate of $0.33. The consensus estimate for Alkermes’ current full-year earnings is $2.25 per share. Zacks Research also issued estimates for Alkermes’ Q3 2025 earnings at $0.33 EPS, Q4 2025 earnings at $0.36 EPS, Q1 2026 earnings at $0.35 EPS and FY2026 earnings at $1.56 EPS.

A number of other analysts have also recently commented on ALKS. Stifel Nicolaus raised shares of Alkermes from a “hold” rating to a “buy” rating and upped their price target for the company from $25.00 to $36.00 in a research report on Tuesday, November 5th. Piper Sandler reiterated an “overweight” rating and issued a $37.00 target price (down from $38.00) on shares of Alkermes in a report on Friday, October 25th. Cantor Fitzgerald cut their price target on Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. The Goldman Sachs Group lowered their price objective on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Finally, HC Wainwright restated a “neutral” rating and issued a $37.00 price target on shares of Alkermes in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $36.00.

Alkermes Trading Up 0.2 %

ALKS opened at $28.54 on Wednesday. Alkermes has a twelve month low of $22.90 and a twelve month high of $32.88. The company has a fifty day moving average of $29.17 and a 200-day moving average of $27.63. The stock has a market cap of $4.62 billion, a PE ratio of 14.64, a price-to-earnings-growth ratio of 1.03 and a beta of 0.49. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22.

Insider Buying and Selling at Alkermes

In other news, Director Cato T. Laurencin sold 2,691 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $31.85, for a total value of $85,708.35. Following the completion of the sale, the director now owns 23,013 shares in the company, valued at $732,964.05. This represents a 10.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Craig C. Hopkinson sold 61,151 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $32.07, for a total transaction of $1,961,112.57. Following the transaction, the executive vice president now owns 47,576 shares in the company, valued at approximately $1,525,762.32. This trade represents a 56.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 147,738 shares of company stock worth $4,572,904. Insiders own 4.89% of the company’s stock.

Institutional Trading of Alkermes

A number of hedge funds have recently bought and sold shares of the business. V Square Quantitative Management LLC bought a new position in Alkermes during the third quarter valued at about $29,000. Ashton Thomas Private Wealth LLC bought a new position in shares of Alkermes during the 2nd quarter valued at approximately $116,000. GAMMA Investing LLC increased its stake in shares of Alkermes by 83.8% during the 3rd quarter. GAMMA Investing LLC now owns 4,204 shares of the company’s stock worth $118,000 after purchasing an additional 1,917 shares during the last quarter. Archer Investment Corp raised its holdings in shares of Alkermes by 28.6% in the 3rd quarter. Archer Investment Corp now owns 4,500 shares of the company’s stock worth $126,000 after purchasing an additional 1,000 shares during the period. Finally, KBC Group NV lifted its stake in Alkermes by 18.8% in the third quarter. KBC Group NV now owns 4,890 shares of the company’s stock valued at $137,000 after purchasing an additional 774 shares during the last quarter. 95.21% of the stock is currently owned by institutional investors.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.